Omnicell, Inc. (NASDAQ:OMCL) Sees Large Drop in Short Interest

Omnicell, Inc. (NASDAQ:OMCL) was the recipient of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 2,259,277 shares, a drop of 15.7% from the January 15th total of 2,680,297 shares. Based on an average trading volume of 335,834 shares, the short-interest ratio is presently 6.7 days. Currently, 5.2% of the company’s shares are short sold. Currently, 5.2% of the company’s shares are short sold. Based on an average trading volume of 335,834 shares, the short-interest ratio is presently 6.7 days.

Omnicell Price Performance

NASDAQ:OMCL opened at $36.50 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The company has a 50 day moving average price of $46.04 and a 200-day moving average price of $37.40. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.00. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 912.73, a price-to-earnings-growth ratio of 1.35 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The business had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. During the same quarter last year, the business earned $0.60 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities research analysts forecast that Omnicell will post 1.09 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, February 9th. Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research note on Wednesday, January 7th. Wells Fargo & Company upped their target price on Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Finally, Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a report on Wednesday, February 4th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.50.

Insider Activity at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.52% of the company’s stock.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its stake in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after buying an additional 5,311 shares during the last quarter. Empowered Funds LLC increased its holdings in Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after acquiring an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Omnicell by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after acquiring an additional 4,866 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Omnicell by 201.5% in the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Omnicell by 2.1% in the second quarter. Nordea Investment Management AB now owns 125,969 shares of the company’s stock valued at $3,739,000 after purchasing an additional 2,580 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.